CNBC's Meg Tirrell reports on the biggest health issues and how industry leaders are thinking about the future of health care in America. David Gluckman, Lazard co-head of health care, weighs in.
CNBC's Meg Tirrell reports on Puma's stock spike after the FDA board votes in support of its breast cancer drug.
CNBC's Meg Tirrell reports on the FDA approving Puma Biotech's breast cancer drug, which sent shares of the company higher.
CNBC's Meg Tirrell reports Neurocrine's stock fell after hours following reports it's drug trial for a new Tourette's medication had failed.
Jeff Leiden, Vertex Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about his company's cystic fibrosis drugs and the future for biotech and pharma under the current administration.
CNBC's Meg Tirrell reports on Amgen stocks falling today after a drug risk.
CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.
CNBC's Meg Tirrell reports on the drug stocks reacting to the data dump. The "Fast Money" traders weigh in.
CNBC's Meg Tirrell reports the latest out of Johnson & Johnson's analyst day, and discusses the company's growing pharmaceutical business.
CNBC's Meg Tirrell reports on the biotech stocks to watch, including a new player Incyte, as well as Johnson and Johnson's analyst day and Amazon's pharmaceutical break in. "Fast Money Halftime Report" traders and Kevin O'Leary weigh in.